Clare L. Parish

Prof. Clare L. Parish

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2000 in Neuroscience
Verified
Journal Article
Closed access
DFDavid Finkelstein
David Finkelstein
DSD. Stanic
D. Stanic
CPClare L. Parish
Clare L. Parish
DTD. Tomas
D. Tomas
KDK. Dickson
K. Dickson
MHM.K. Horne
M.K. Horne

22 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
IJIbrahim Javed
Ibrahim Javed
Guotao PengGuotao Peng
Guotao Peng
YXYanting Xing
Yanting Xing
TYTianyu Yu
Tianyu Yu
MZMei Zhao
Mei Zhao
Sijie LinSijie Lin
Sijie Lin
Alzheimer’s disease (AD) is the most prevalent form of neurodegenerative disorders, yet no major breakthroughs have been made in AD human trials and the disease remains a paramount challenge and a stigma in medicine. Here we eliminate the toxicity of amyloid beta (Aβ) in a facile, high-throughput zebrafish (Danio rerio) model using casein coated-gold nanoparticles (βCas AuNPs). βCas AuNPs in systemic circulation translocate across the blood brain barrier of zebrafish larvae and sequester intracerebral Aβ42 and its elicited toxicity in a nonspecific, chaperone-like manner. This is evidenced by behavioral pathology, reactive oxygen species and neuronal dysfunction biomarkers assays, complemented by brain histology and inductively coupled plasma-mass spectroscopy. We further demonstrate the capacity of βCas AuNPs in recovering the mobility and cognitive function of adult zebrafish exposed to Aβ. This potent, safe-to-use, and easy-to-apply nanomedicine may find broad use for eradicating toxic amyloid proteins implicated in a range of human diseases.

1 November 2002 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
PBP E Batchelor
P E Batchelor
MPM J Porritt
M J Porritt
PMP Martinello
P Martinello
CPClare L. Parish
Clare L. Parish
GLG T Liberatore
G T Liberatore
DHD W Howells
D W Howells

1 June 2010 in Stem Cells and Development
Verified
Journal Article
Closed access
MHMalcolm K. Horne
Malcolm K. Horne
David NisbetDavid Nisbet
David Nisbet
JFJohn S. Forsythe
John S. Forsythe
CPClare L. Parish
Clare L. Parish
Attempts to repair the central nervous system damaged as a result of trauma or disease will depend on the ability to restore the appropriate neuronal connectivity. This will rely on establishing appropriate chemical and physical environments for supporting neural cells and their processes and in this regard, engineering of biomaterials is of increasing interest. It will be important to understand how cells behave on these biomaterials in vitro, prior to future in vivo application. We reveal that modification of 3-dimensional (3D) electrospun poly-ε-caprolactone (PCL) nanofiber scaffolds by fiber alignment and aminolysation is superior to classical 2-dimensional (2D) culture-ware in promoting in vitro proliferation and differentiation of cortical cells. Many studies have examined the importance of exogenous soluble factors to promote cell fate specification. Here, we demonstrate that tethering the neurotrophin, brain-derived neurotrophic factor (BDNF), onto modified nanofibers is superior to culturing in the presence of soluble BDNF. Functional immobilization of BDNF to polymer nanofibers enhances neural stem cell (NSC) proliferation and directs cell fate toward neuronal and oligodendrocyte specification, essential for neural tissue repair. These findings indicate that modified PCL nanofibrous 3D scaffolds are capable of supporting NSCs and their derivatives and may present a new avenue for encouraging neural repair in the future.

2 January 2008 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CPClare L. Parish
Clare L. Parish
GCGonçalo Castelo-Branco
Gonçalo Castelo-Branco
NRNina Rawal
Nina Rawal
JTJan Tonnesen
Jan Tonnesen
ASAndreas Toft Sorensen
Andreas Toft Sorensen
EAErnest Arenas
Ernest Arenas
Dopamine (DA) cell replacement therapy in Parkinson disease (PD) can be achieved using human fetal mesencephalic tissue; however, limited tissue availability has hindered further developments. Embryonic stem cells provide a promising alternative, but poor survival and risk of teratoma formation have prevented their clinical application. We present here a method for generating large numbers of DA neurons based on expanding and differentiating ventral midbrain (VM) neural stem cells/progenitors in the presence of key signals necessary for VM DA neuron development. Mouse VM neurospheres (VMNs) expanded with FGF2, differentiated with sonic hedgehog and FGF8, and transfected with Wnt5a (VMN-Wnt5a) generated 10-fold more DA neurons than did conventional FGF2-treated VMNs. VMN-Wnt5a cells exhibited the transcriptional and biochemical profiles and intrinsic electrophysiological properties of midbrain DA cells. Transplantation of these cells into parkinsonian mice resulted in significant cellular and functional recovery. Importantly, no tumors were detected and only a few transplanted grafts contained sporadic nestin-expressing progenitors. Our findings show that Wnt5a improves the differentiation and functional integration of stem cell–derived DA neurons in vivo and define Wnt5a-treated neural stem cells as an efficient and safe source of DA neurons for cell replacement therapy in PD.

1 October 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
PSPaola Sacchetti
Paola Sacchetti
KSKyle M. Sousa
Kyle M. Sousa
AHAnita C. Hall
Anita C. Hall
ILIsabel Liste
Isabel Liste
KSKnut R. Steffensen
Knut R. Steffensen
EAErnest Arenas
Ernest Arenas